DCVax’s selection criteria is on par with all other GBM trials, and seems to be faring better. All clinical trials whittle their patients down from the general pool, and NWBO’s is extremely similar to comparators based on age, methylated status, etc—and yes, REP. If you think their selection criteria is nefarious, go ahead and compare it to other recent GBM trials. You’ll see little difference. And yet, DCVax blended data is better than the pack. That seems to be consistent with... hmm.
Market Data 
Markets 
AI
